Biomea Fusion, Inc. (BMEA)Healthcare | Biotechnology | San Carlos, United States | NasdaqGS
1.33 USD
+0.01
(0.758%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:36 a.m. EDT
The investment case for Biomea Fusion is currently defined by severe distress rather than opportunity. Fundamentally, the company is bleeding cash with negative free cash flow and a deteriorating balance sheet, while the stock has erased nearly 88% of its value over the last four years. Although recent news highlights positive diabetes trial results and insider buying, these catalysts have failed to arrest the multi-year decline, leaving the stock trading at a premium to its book value despite having no earnings. The options market confirms this pessimism, with traders aggressively buying puts to hedge against further drops while ignoring the upside. While the clinical data offers a theoretical path to recovery, the execution risk and capital constraints make this a high-risk speculative play rather than a viable investment, warranting a strong avoidance rating for the long term and a bearish lean for the near term. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.112533 |
| AutoETS | 0.118512 |
| AutoARIMA | 0.119619 |
| AutoTheta | 0.148397 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 2.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.607 |
| Excess Kurtosis | -0.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.619 |
| Market Cap | 96,158,256 |
| Forward P/E | -1.21 |
| Beta | -0.33 |
| Website | https://biomeafusion.com |
As of July 11, 2026, 6:36 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive put volume and open interest concentrated at strikes above the current price ($2.00-$2.50). Call activity is negligible and skewed toward deep out-of-the-money strikes, indicating a lack of near-term bullish conviction despite some speculative longing for a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31958765 |
| Address1 | 1,599 Industrial Road |
| All Time High | 43.69 |
| All Time Low | 0.872 |
| Ask | 1.6 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 1,238,960 |
| Average Daily Volume3 Month | 1,266,975 |
| Average Volume | 1,266,975 |
| Average Volume10Days | 1,238,960 |
| Beta | -0.329 |
| Bid | 0.9576 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.259 |
| City | San Carlos |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.33 |
| Current Ratio | 4.984 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.34 |
| Day Low | 1.24 |
| Debt To Equity | 6.619 |
| Display Name | Biomea Fusion |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | -63,382,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.832 |
| Enterprise Value | 52,704,256 |
| Eps Current Year | -1.08059 |
| Eps Forward | -1.10294 |
| Eps Trailing Twelve Months | -0.56 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3463 |
| Fifty Day Average Change | -0.016299963 |
| Fifty Day Average Change Percent | -0.01210723 |
| Fifty Two Week Change Percent | -31.958765 |
| Fifty Two Week High | 2.99 |
| Fifty Two Week High Change | -1.66 |
| Fifty Two Week High Change Percent | -0.55518395 |
| Fifty Two Week Low | 0.872 |
| Fifty Two Week Low Change | 0.45800006 |
| Fifty Two Week Low Change Percent | 0.52522945 |
| Fifty Two Week Range | 0.872 - 2.99 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,579,800,000 |
| Float Shares | 67,444,533 |
| Forward Eps | -1.10294 |
| Forward P E | -1.205868 |
| Free Cashflow | -34,450,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07166 |
| Held Percent Institutions | 0.38881 |
| Implied Shares Outstanding | 72,299,440 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California. |
| Long Name | Biomea Fusion, Inc. |
| Market | us_market |
| Market Cap | 96,158,256 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_695310535 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -44,950,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 96,519,752 |
| Number Of Analyst Opinions | 6 |
| Open | 1.32 |
| Operating Cashflow | -56,373,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 650 980 9099 |
| Pre Market Change | 0.046199918 |
| Pre Market Change Percent | 3.4736779 |
| Pre Market Price | 1.3762 |
| Pre Market Time | 1,784,016,019 |
| Previous Close | 1.32 |
| Price Eps Current Year | -1.2308091 |
| Price Hint | 4 |
| Price To Book | 5.135135 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.809 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.757575 |
| Regular Market Day High | 1.34 |
| Regular Market Day Low | 1.24 |
| Regular Market Day Range | 1.24 - 1.34 |
| Regular Market Open | 1.32 |
| Regular Market Previous Close | 1.32 |
| Regular Market Price | 1.33 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,046,986 |
| Return On Assets | -0.79319 |
| Return On Equity | -1.89439 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,299,440 |
| Shares Percent Shares Out | 0.19129999 |
| Shares Short | 13,830,845 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 14,480,424 |
| Short Name | Biomea Fusion, Inc. |
| Short Percent Of Float | 0.2333 |
| Short Ratio | 13.27 |
| Source Interval | 15 |
| State | CA |
| Symbol | BMEA |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 6.83333 |
| Target Median Price | 7.0 |
| Total Cash | 44,693,000 |
| Total Cash Per Share | 0.618 |
| Total Debt | 1,239,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.56 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.42032 |
| Two Hundred Day Average Change | -0.09031999 |
| Two Hundred Day Average Change Percent | -0.063591294 |
| Type Disp | Equity |
| Volume | 1,046,986 |
| Website | https://biomeafusion.com |
| Zip | 94,070 |